Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry.
Calafat M, Mañosa M, Ricart E, Nos P, Iglesias-Flores E, Vera I, López-Sanromán A, Guardiola J, Taxonera C, Mínguez M, Martín-Arranz MD, de Castro L, de Francisco R, Rivero M, Garcia-Planella E, Calvet X, García-López S, Márquez L, Gomollón F, Barrio J, Esteve M, Muñoz F, Gisbert JP, Gutiérrez A, Hinojosa J, Argüelles-Arias F, Busquets D, Bujanda L, Pérez-Calle JL, Sicilia B, Merino O, Martínez P, Bermejo F, Lorente R, Barreiro-de Acosta M, Rodríguez C, Fe García-Sepulcre M, Monfort D, Cañete F, Domènech E; ENEIDA Study Group of GETECCU. Calafat M, et al. Among authors: de castro l, de francisco r. J Crohns Colitis. 2022 Jul 14;16(6):946-953. doi: 10.1093/ecco-jcc/jjab213. J Crohns Colitis. 2022. PMID: 34864947
High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
Martínez-Borra J, López-Larrea C, González S, Fuentes D, Dieguez A, Deschamps EM, Pérez-Pariente JM, López-Vázquez A, de Francisco R, Rodrigo L. Martínez-Borra J, et al. Among authors: de francisco r. Am J Gastroenterol. 2002 Sep;97(9):2350-6. doi: 10.1111/j.1572-0241.2002.05990.x. Am J Gastroenterol. 2002. PMID: 12358255
Kaposi's sarcoma: an opportunistic infection by human herpesvirus-8 in ulcerative colitis.
Rodríguez-Peláez M, Fernández-García MS, Gutiérrez-Corral N, de Francisco R, Riestra S, García-Pravia C, Rodríguez JI, Rodrigo L. Rodríguez-Peláez M, et al. Among authors: de francisco r. J Crohns Colitis. 2010 Nov;4(5):586-90. doi: 10.1016/j.crohns.2010.03.006. Epub 2010 Apr 20. J Crohns Colitis. 2010. PMID: 21122564
Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study.
Nunes T, Barreiro-de Acosta M, Nos P, Marin-Jiménez I, Bermejo F, Ceballos D, Iglesias E, Gomez-Senent S, Torres Y, Ponferrada A, Arevalo JA, Hernandez V, Calvet X, Ginard D, Monfort D, Chaparro M, Manceñido N, Domínguez-Antonaya M, Villalón C, Perez-Calle JL, Muñoz C, Nuñez H, Carpio D, Aramendiz R, Bujanda L, Estrada-Oncins S, Hermida C, Barrio J, Casis MB, Dueñas-Sadornil MC, Fernández L, Calvo-Cenizo MM, Botella B, de Francisco R, Ayala E, Sans M; RECLICU Study Group of GETECCU. Nunes T, et al. Among authors: de francisco r. J Crohns Colitis. 2010 Dec;4(6):629-36. doi: 10.1016/j.crohns.2010.07.003. J Crohns Colitis. 2010. PMID: 21122572
Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment.
Carpio D, Jauregui-Amezaga A, de Francisco R, de Castro L, Barreiro-de Acosta M, Mendoza JL, Mañosa M, Ollero V, Castro B, González-Conde B, Hervías D, Sierra Ausin M, Sancho Del Val L, Botella-Mateu B, Martínez-Cadilla J, Calvo M, Chaparro M, Ginard D, Guerra I, Maroto N, Calvet X, Fernández-Salgado E, Gordillo J, Rojas Feria M; GETECCU. Carpio D, et al. Among authors: de castro l, de francisco r. J Crohns Colitis. 2016 Oct;10(10):1186-93. doi: 10.1093/ecco-jcc/jjw022. Epub 2016 Jan 22. J Crohns Colitis. 2016. PMID: 26802085 Free article.
Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent.
R-Grau Mdel C, Chaparro M, Mesonero F, Barreiro-de Acosta M, Castro L, Castro M, Domènech E, Mancenido N, Pérez-Calle JL, Taxonera C, Barrio J, De Francisco R, Fernández-Salgado E, Luzón L, Merino O, Oltra L, Saro C, Bermejo F, García-Sánchez V, Ginard D, Gutiérrez A, Vera I, Antón R, Ber Y, Calvet X, Gisbert JP. R-Grau Mdel C, et al. Among authors: de francisco r. Dig Liver Dis. 2016 Jun;48(6):613-9. doi: 10.1016/j.dld.2016.02.012. Epub 2016 Mar 2. Dig Liver Dis. 2016. PMID: 26992847
Risk factors for tuberculosis in inflammatory bowel disease: anti-tumor necrosis factor and hospitalization.
Riestra S, de Francisco R, Arias-Guillén M, Saro C, García-Alvarado M, Duque JM, Palacios JJ, Muñoz F, Blanco L, Castaño O, Pérez-Martínez I, Martínez-Camblor P, Pérez Hernández D, Suárez A. Riestra S, et al. Among authors: de francisco r. Rev Esp Enferm Dig. 2016 Sep;108(9):541-9. doi: 10.17235/reed.2016.4440/2016. Rev Esp Enferm Dig. 2016. PMID: 27604582 Free article.
Clinical status, quality of life, and work productivity in Crohn's disease patients after one year of treatment with adalimumab.
Saro C, Ceballos D, Muñoz F, de la Coba C, Aguilar MD, Lázaro P, García-Sánchez V, Hernández M, Barrio J, de Francisco R, Fernández LI, Barreiro-de Acosta M. Saro C, et al. Among authors: de la coba c, de francisco r. Rev Esp Enferm Dig. 2017 Feb;109(2):122-129. doi: 10.17235/reed.2016.4600/2016. Rev Esp Enferm Dig. 2017. PMID: 28026199 Free article.
82 results